로딩 중...
52주 최고가 대비 79.2% 위치
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.
SEC 13F 공시 기준 · 2026-Q1
SEC 13F 공시 기준 데이터입니다. 실제 현재 보유 현황과 다를 수 있으며, 투자 자문·권유·추천이 아닙니다.
| 재무 항목 | 2021년 | 2022년 | 2023년 | 2024년 | 2025년 |
|---|---|---|---|---|---|
| 주요 재무실적 (USD) | |||||
| 매출액 | - | $3.77B | $4.15B | $4.79B | $5.10B |
| 영업이익 | - | $220.0M | $204.0M | $206.0M | $188.0M |
| 당기순이익 | - | $6.0M | $-260.0M | $-317.0M | $-360.0M |
| 잉여현금흐름 (FCF) | - | $170.0M | $-198.0M | $-59.0M | $-66.0M |
| 수익성 비율 | |||||
| 영업이익률 | - | 5.8% | 4.9% | 4.3% | 3.7% |
| 순이익률 | - | 0.2% | -6.3% | -6.6% | -7.1% |
| ROE (자기자본이익률) | - | 0.1% | -3.8% | -4.9% | -5.6% |
| ROA (자산이익률) | - | 0.1% | -1.9% | -2.4% | -2.6% |
| 성장성 비율 | |||||
| 매출 성장률 (YoY) | - | - | 10.0% | 15.6% | 6.5% |
| EPS 성장률 (YoY) | - | - | -3800.0% | -21.6% | -13.3% |
| 투자 지표 & 가치배수 | |||||
| PER (주가수익배수) | - | 862.0x | - | - | - |
| PBR (주가순자산배수) | - | 0.9x | 0.7x | 1.0x | 0.9x |
| PSR (주가매출배수) | - | 1.6x | 1.2x | 1.3x | 1.2x |
| FCF Yield | - | 2.8% | -4.0% | -1.0% | -1.1% |
| 재무 건전성 (안정성) | |||||
| 부채비율 (D/E) | - | 0.35 | 0.67 | 0.74 | 0.79 |
| 유동비율 | - | 1.65 | 1.74 | 1.60 | 1.55 |
MOLINA HEALTHCARE INC
$179.86
$9.4B